Phase II Ivonescimab: PD-1/VEGF-targeted bispecific antibody in thymic carcinoma.

This trial examines ivonescimab monotherapy in previously treated thymic carcinoma patients with IV infusions every three weeks. Patients undergo CT scans and biospecimen collection to assess treatment effects. Sponsored by Jonsson Comprehensive Cancer Center, the study explores safety, efficacy, and biomarker insights in a novel immunotherapy approach.